Elina Mercier unlocks scientific barriers on oculocutaneous albinism at the University of Bordeaux

Elina Mercier, a researcher at the University of Bordeaux, has identified new pathogenic variants related to oculocutaneous albinism, paving the way for advanced genetic diagnostics. This research, validated by the ABES/STAR network, addresses an urgent need in West Africa, where the condition is often misunderstood and leads to medical and social challenges.

Oculocutaneous albinism, a rare genetic disease, affects pigmentation and is the leading cause of congenital blindness. In West Africa, this condition affects many individuals, often stigmatized. Elina Mercier's research aims to identify the underlying pathophysiological mechanisms and improve the understanding of the genetic variants associated with this disease.

Mercier's work has led to a better understanding of the splicing of exon 10 of the OCA2 gene, essential for the production of tyrosinase, a key enzyme in melanin synthesis. By identifying new pathogenic variants, this research enhances the prospects for more accurate diagnostics for patients with albinism.

The results of this research have strategic implications for the development of advanced genetic diagnostics, promoting better patient care. Decision-makers must support these initiatives to meet the growing demand for precise solutions in the field of rare diseases.

« « By deepening the understanding of the molecular mechanisms involved in albinism, we can offer more accurate diagnostics tailored to the needs of patients, » says Elina Mercier. »

« « Elina Mercier's work illustrates the importance of access to knowledge to transform research into concrete solutions for decision-makers, » emphasizes the Lektaris team. »